October 2001
Worldwide Biotech;Oct2001, Vol. 13 Issue 10, p3
Trade Publication
Reports that St. Jude Medical Inc. has received Communaute Europeenne Mark approval for its stentless tissue valve, the Toronto Root bioprosthesis.


Related Articles

  • Product Briefs.  // Biomedical Business & Technology;Dec2011, Vol. 34 Issue 12, p24 

    The article offers information on the results of a feasibility study conducted by St. Paul, Minnesota-based St. Jude Medical Inc. for its Portico transcathe-ter aortic heart valve that have demonstrated its efficacy.

  • St. Jude garners CE mark for Trifecta.  // Medical Device Daily;3/3/2010, Vol. 14 Issue 41, p8 

    The article reports on the clinical excellence (CE)-mark approval received by St. Jude Medical for its Trifecta pericardial aortic stented tissue valve.

  • Hundreds of thousands of hearts made healthier in Caguas. Ruano, Lida Estela // Caribbean Business;5/4/2000, Vol. 28 Issue 17, p35 

    Features Saint Jude Medical P.R. Inc., a manufacturing plant in Puerto Rico that produces 90 percent of heart valves used in the United States and more than half of those used worldwide. Total annual heart valve sales of the company; Average cost of the valves; Plant's ISO 9001 certification;...

  • prosthetic heart valve market is dominated by three leading companies: Edwards Lifesciences; St. Jude Medical and Medtronic.  // Biomedical Market Newsletter;8/12/2011, Vol. 21, p764 

    The article reports that the prosthetic heart valve market is dominated by Edwards Lifesciences Corp., St. Jude Medical Inc. and Medtronic Inc. in London, England, according to a report "Prosthetic Heart Valves: A Global Strategic Business Report." It states that the market growth is driven by...

  • St. Jude Medical launches new Trifecta heart valve in Japan.  // Medical Device Daily;4/18/2012, Vol. 16 Issue 75, p1 

    The article reports that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted regulatory approval for the Trifecta aortic stented, pericardial tissue valve from St. Jude Medical. It describes the Trifecta valve for patients with diseased, damaged or malfunctioning heart valves....

  • St. Jude Medical Portico Transcatheter Valve Demonstrates Promising Results in Feasibility Study.  // Biomedical Market Newsletter;11/14/2011, Vol. 21, p594 

    The article reports on the results of a feasibility study for St. Jude Medical Inc.'s Portico Transcatheter Aortic Heart Valve which was presented at the 23rd Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. The study reportedly revealed that the device demonstrated...

  • Prosthetic Heart Valves Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017.  // Biomedical Market Newsletter;9/26/2011, Vol. 21, p407 

    The article presents the report "Prosthetic Heart Valves Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017" from GlobalData. It provides value data for each segment within the market categories of heart valves and shares data of company in the BRICS countries. It is...

  • HEART OF THE MATTER. Giammona, Craig // Fortune;11/18/2013, Vol. 168 Issue 8, p24 

    The article focuses on St. Jude Medical founded in 1976 and grew to become one of the world's top sellers of heart valves. St. Jude completed a 500 million U.S. dollars deal with Siemens to purchase Pacesetter in 1994 when its stock was trading at just under 6 U.S. dollars. St. Jude's stock has...

  • Edwards Lifesciences Falls as Sales Miss Forecast. Edwards Lifesciences Corp.  // MondayMorning;10/15/2012, Vol. 20 Issue 39, p1 

    The article offers information on Edwards Lifesciences Corp., an artificial maker of heart valve that had a huge loss in past 12 months, following its loss in 2012 third-quarter sales. It mentions that the sale was below the company's expectation and its forecast proved wrong with the decline in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics